LENZ
LENZ Therapeutics, Inc. NASDAQ$9.28
Mkt Cap $291.0M
52w Low $8.25
2.4% of range
52w High $50.40
50d MA $10.63
200d MA $24.62
P/E (TTM)
-3.1x
EV/EBITDA
-4.8x
P/B
0.9x
Debt/Equity
0.0x
ROE
-28.9%
P/FCF
-6.6x
RSI (14)
—
ATR (14)
—
Beta
2.29
50d MA
$10.63
200d MA
$24.62
Avg Volume
942.1K
About
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | -0.91 | -1.16 | -27.5% | 9.03 | +1.8% | +0.4% | -1.0% | -7.0% | -8.2% | +1.3% | — |
| Nov 5, 2025 | AMC | -0.67 | -0.59 | +11.9% | 21.47 | +3.0% | +6.9% | +7.0% | +8.0% | +23.2% | +18.8% | — |
| Jul 30, 2025 | AMC | -0.58 | -0.53 | +8.6% | 30.76 | -0.7% | -3.2% | -2.6% | -4.6% | -0.9% | -1.9% | — |
| May 7, 2025 | AMC | -0.55 | -0.53 | +3.6% | 25.34 | +0.0% | +2.1% | +3.9% | +15.9% | +14.3% | +9.0% | — |
| Mar 19, 2025 | AMC | -0.42 | -0.46 | -9.5% | 25.52 | +8.0% | +3.1% | +3.8% | +4.5% | +3.6% | +2.2% | — |
| Nov 6, 2024 | AMC | -0.47 | -0.38 | +19.1% | 32.23 | -0.7% | +0.9% | +8.8% | +10.9% | +15.6% | +12.8% | — |
| Aug 14, 2024 | AMC | -0.49 | -0.40 | +18.4% | 23.50 | +1.1% | -3.8% | -3.2% | -3.4% | -4.3% | -4.4% | — |
| May 8, 2024 | AMC | -0.84 | -3.53 | -320.2% | 16.18 | -1.6% | -4.8% | -2.8% | -1.7% | -2.8% | -2.1% | — |
| Feb 27, 2024 | AMC | -0.13 | -0.40 | -207.7% | 14.96 | +2.5% | +3.7% | +7.2% | +7.2% | +5.0% | +2.2% | — |
| Nov 13, 2023 | AMC | -0.25 | -0.19 | +24.0% | 10.89 | +2.1% | +1.3% | -2.2% | -2.0% | +1.3% | +2.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.13 | $10.12 | -0.1% | -2.6% | -1.4% | -9.7% | -7.4% | -3.7% |
| Mar 26 | Citigroup | Maintains | Buy → Buy | — | $9.07 | $8.91 | -1.8% | -1.4% | -7.4% | -8.6% | +0.9% | +3.1% |
| Mar 25 | BofA Securities | Maintains | Buy → Buy | — | $9.03 | $9.19 | +1.8% | +0.4% | -1.0% | -7.0% | -8.2% | +1.3% |
| Oct 20 | Raymond James | Maintains | Outperform → Outperform | — | $38.26 | $39.17 | +2.4% | -5.1% | -12.3% | -14.5% | -18.0% | -16.4% |
| Oct 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $46.25 | $46.75 | +1.1% | -16.1% | -16.5% | -16.1% | -9.5% | -12.5% |
| Aug 1 | Citigroup | Maintains | Buy → Buy | — | $29.77 | $30.01 | +0.8% | +0.6% | -1.5% | +2.4% | +1.3% | +7.9% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.77 | $30.01 | +0.8% | +0.6% | -1.5% | +2.4% | +1.3% | +7.9% |
| Jul 31 | Citigroup | Maintains | Buy → Buy | — | $30.76 | $30.55 | -0.7% | -3.2% | -2.6% | -4.6% | -0.9% | -1.9% |
| Jul 31 | Raymond James | Maintains | Outperform → Outperform | — | $30.76 | $30.55 | -0.7% | -3.2% | -2.6% | -4.6% | -0.9% | -1.9% |
| Jul 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.62 | $33.35 | +5.5% | -0.3% | +0.2% | -2.7% | -5.9% | -5.2% |
Recent Filings
Data updated apr 25, 2026 6:51pm
· Source: massive.com